Gilead Sciences announces the acquisition of CymaBay Therapeutics
Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced yesterday a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver […]
Matica Bio designates Paul Kim as CEO
Matica Biotechnology, Inc., a contract development and manufacturing organization (CDMO) of cell and gene therapies (CGTs), yesterday announced the appointment of Paul Kim as chief executive officer (CEO). As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands its capacity and capabilities in the U.S. and […]
Molecular Partners and Orano Med collaborate to develop novel Radio-DARPin therapeutics
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a pioneer in targeted alpha therapy, have announced a collaboration to develop novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to selectively kill cancer cells. Both companies will leverage their […]
HebeCell and Logomix collaborate to develop gene-edited NK cells
HebeCell Corp (HebeCell), a biotechnology company developing ProtoNK™ cell therapeutics based on its proprietary 3D PSC-NK manufacture platform, and Logomix Inc (Logomix), a Tokyo-based synthetic biology company, with a platform technology to engineer-in complex genomic messages of ~Mb-scale into human cells, recently announced a strategic partnership to research and develop gene-edited NK cells and discover genetic […]
Vial appoints Emma C. Moran as the new VP of Central Nervous Systems
Vial, a global tech-driven CRO providing next-generation clinical trial management services, announced the addition of Emma C. Moran to their team. Moran will be the CRO’s new VP of Central Nervous Systems (CNS), bringing with her an impressive 28-year track record in the clinical research industry. Moran’s expertise spans various domains within the pharmaceutical sector, having worked with both […]
Heligenics announces precision genetics test for breast cancer therapeutics
Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs to treat breast cancer. There are multiple drugs available to treat breast cancer. Most patients become drug resistant, meaning that the cancer cells aren’t responding to the drug that is usually able to kill or weaken them. Although many patients […]
SARC welcomes Dr. Jonathan Fletcher as Chief Scientific Officer
SARC (Sarcoma Alliance for Research Through Collaboration) had recently announced to welcome Dr. Jonathan Fletcher, M.D., to been elected for latest role of Chief Scientific Officer (CSO). The firm is a non-profit cancer research organization powering out a collaborative discovery, translational research, clinical trials in sarcoma, a form of cancer that influences children, adults. Within […]
